Caribou Biosciences, Inc. Increase (Decrease) in Accrued Liabilities
Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Accrued Liabilities of -$3.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$744.00K, a 208.14% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$2.65M.
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$2.82M.
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$1.11M, a 170.41% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$6.34M, a 397.09% decline from fiscal 2024.
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $2.13M, a 62.84% decline from fiscal 2023.
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $5.74M, a 194.06% increase from fiscal 2022.
- Caribou Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $1.95M, a 54.38% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$744.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.39M 10-Q · filed 2026-08-13 | -$6.21M derived: sum of 3 quarters · filed 2026-08-13 | -$7.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.65M 10-Q · filed 2026-05-07 | -$5.46M derived: sum of 2 quarters · filed 2026-05-07 | -$6.57M derived: sum of 3 quarters · filed 2026-05-07 | -$5.88M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$3.93M derived: sum of 2 quarters · filed 2026-03-05 | -$3.24M derived: sum of 3 quarters · filed 2026-08-13 | -$6.34M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$423.00K derived: sum of 2 quarters · filed 2026-08-13 | -$3.52M 10-Q · filed 2025-11-12 | -$5.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $688.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.41M 10-Q · filed 2026-08-13 | -$4.62M derived: sum of 3 quarters · filed 2026-08-13 | -$3.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$3.10M 10-Q · filed 2026-05-07 | -$5.31M derived: sum of 2 quarters · filed 2026-05-07 | -$3.73M derived: sum of 3 quarters · filed 2026-05-07 | $1.24M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$629.00K derived: sum of 2 quarters · filed 2026-03-05 | $4.34M derived: sum of 3 quarters · filed 2026-03-05 | $2.13M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.54M derived: sum of 2 quarters · filed 2025-11-12 | $4.34M 10-Q · filed 2025-11-12 | $7.24M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.76M 10-Q · filed 2025-08-12 | $5.66M derived: sum of 3 quarters · filed 2025-08-12 | $8.94M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.20M 10-Q · filed 2025-05-08 | $691.00K derived: sum of 2 quarters · filed 2025-05-08 | $3.97M derived: sum of 3 quarters · filed 2025-05-08 | $7.68M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $6.17M derived: sum of 2 quarters · filed 2025-03-10 | $9.88M derived: sum of 3 quarters · filed 2025-03-10 | $5.74M 10-K · filed 2025-03-10 |
| 2023-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.99M derived: sum of 2 quarters · filed 2024-11-06 | $2.85M 10-Q · filed 2024-11-06 | $3.89M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $3.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$431.00K 10-Q · filed 2024-08-06 | $613.00K derived: sum of 3 quarters · filed 2024-08-06 | $405.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$4.14M 10-Q · filed 2024-05-07 | -$3.09M derived: sum of 2 quarters · filed 2024-05-07 | -$3.30M derived: sum of 3 quarters · filed 2024-05-07 | $646.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $836.00K derived: sum of 2 quarters · filed 2024-03-11 | $4.78M derived: sum of 3 quarters · filed 2024-03-11 | $1.95M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.74M derived: sum of 2 quarters · filed 2023-11-07 | $909.00K 10-Q · filed 2023-11-07 | $335.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.12M 10-Q · filed 2023-08-08 | $543.00K derived: sum of 3 quarters · filed 2023-08-08 | $4.39M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$2.83M 10-Q · filed 2023-05-09 | -$3.40M derived: sum of 2 quarters · filed 2023-05-09 | $441.00K derived: sum of 3 quarters · filed 2023-05-09 | -$2.43M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$574.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.27M derived: sum of 2 quarters · filed 2023-03-09 | $402.00K derived: sum of 3 quarters · filed 2023-03-09 | $4.28M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $976.00K derived: sum of 2 quarters · filed 2022-11-08 | $4.86M 10-Q · filed 2022-11-08 | $6.03M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.01M 10-Q · filed 2022-08-09 | $2.19M derived: sum of 3 quarters · filed 2022-08-09 | $4.20M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $3.88M 10-Q · filed 2022-05-09 | $5.06M derived: sum of 2 quarters · filed 2022-05-09 | $7.07M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $3.19M derived: sum of 2 quarters · filed 2022-03-21 | $2.29M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.11M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$897.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $703.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |